Kanak Raina

Biochemistry, Genetics and Molecular Biology · Life Sciences

18h-index4.2kcitations40works17.72yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Protein Degradation and Inhibitors(32), Multiple Myeloma Research and Treatments(18), Ubiquitin and proteasome pathways(14), Histone Deacetylase Inhibitors Research(8), Prostate Cancer Treatment and Research(7)

Publications40 total

An oral prostate cancer RIPTACtherapeutic in phase 1 for metastatic castrate resistant prostate cancer (mCRPC).
Journal of Clinical Oncology·2025· 1 cited
Abstract LB428: An orally bioavailable RIPTAC™ therapeutic for p53 Y220C mutant tumors
Cancer Research·2025
Regulated induced proximity targeting chimeras—RIPTACs—A heterobifunctional small molecule strategy for cancer selective therapies
Cell chemical biology·2024· 52 citedOpen Access
Abstract 1629: Prostate cancer RIPTAC™ therapeutics demonstrate activity in preclinical models of Enzalutamide-resistant prostate cancer
Cancer Research·2023· 3 cited
An oral androgen receptor RIPTAC for prostate cancer.
Journal of Clinical Oncology·2023· 9 cited
Regulated Induced Proximity Targeting Chimeras (RIPTACs): a Novel Heterobifunctional Small Molecule Therapeutic Strategy for Killing Cancer Cells Selectively
2023· 33 citedOpen Access
RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1
Blood·2019· 96 citedOpen Access
Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML
Leukemia·2018· 42 cited
Disruption of NOTCH1-MYC-CD44 Axis Targets Leukemia Initiating Cells (LIC) in T-ALL
Blood·2018
Abstract 5236: ARV-110: An androgen receptor PROTAC degrader for prostate cancer
Cancer Research·2018· 59 cited
Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma
Leukemia·2018· 80 citedOpen Access
An oral androgen receptor PROTAC degrader for prostate cancer.
Journal of Clinical Oncology·2018· 15 cited
Targeted Therapy with BET Protein and β Catenin Antagonists Against Ruxolitinib Resistant Post-Myeloproliferative Neoplasm (MPN) Secondary (s) AML Cells
Blood·2017
BRD4 Proteolysis Targeting Chimera (PROTAC) ARV-825 Targets Both NOTCH1-MYC Regulatory Circuit and Leukemia-Microenvironment in T-ALL
Blood·2017· 1 cited
Targeted Therapy for AML Expressing RUNX1 Mutation
Blood·2017· 1 cited
Preclinical Activity of Novel BET Protein Proteolysis Targeting Chimeras (BETP-PROTACs) and Their Combination with Venetoclax or CDK4/6 Inhibitor Against Human Mantle Cell Lymphoma (MCL) Cells
Blood·2017
Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1
Journal of Medicinal Chemistry·2017· 246 citedOpen Access
Abstract 5076: IHC and flow cytometry quantifies BRD4 levels in surrogate tissues after ex-vivo and in-vivo dosing with a BRD4 degrading PROTAC
Cancer Research·2017
Abstract 5067: BET protein proteolysis targeting chimera (BETP-PROTACs) exert more potent activity than BETP bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm (MPN) secondary (s) AML cells
Cancer Research·2017
Abstract 5637: An oral Androgen Receptor PROTAC degrader for prostate cancer
Cancer Research·2017· 2 cited
page 1 of 2Next →

Frequent Co-authors

Craig M. Crews(35), Yimin Qian(23), Andrew P. Crew(17), Kevin Coleman(15), Jing Wang(11), Dyana T. Saenz(11), Warren Fiskus(11), Kapil N. Bhalla(11), Hanqing Dong(10), Christopher P. Mill(10), Baohua Sun(10), Martha Altieri(8), Taavi K. Neklesa(8), Jing Lü(7), Agnieszka Nowak(7), John Hines(6), Taghi Manshouri(6), Angela Shen(6), Srđan Verstovšek(6), Kyle J. Eastman(6)